Wafra Inc. Gilead Sciences, Inc. Transaction History

Wafra Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $19.9 Million - $25.9 Million	-328,125 Closed	0 $0
Q2 2018 Aug 09, 2018	BUY	$64.88 - $75.68 $7.59 Million - $8.86 Million	117,015 Added 55.43%	328,125 $23.2 Million
Q1 2018 May 15, 2018	BUY	$72.84 - $88.8 $6.91 Million - $8.43 Million	94,899 Added 81.66%	211,110 $15.9 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $352,904 - $414,259	4,960 Added 4.46%	116,211 $8.33 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $8.02 Million - $9.51 Million	111,251	111,251 $9.01 Million

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Wafra Inc., based on Form 13F filings with the SEC.

Stay updated on Wafra Inc. with notifications on news.